Phio Pharmaceuticals logo

Phio PharmaceuticalsNASDAQ: PHIO

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

10 May 2012

Next earnings report:

N/A

Last dividends:

N/A

Next dividends:

N/A
$2.46 M
-92%vs. 3y high
6%vs. sector
-vs. 3y high
-vs. sector
-69%vs. 3y high
26%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Thu, 21 Nov 2024 00:02:34 GMT
$2.33-$0.22(-8.63%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

PHIO Latest News

Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study
newsfilecorp.com19 November 2024 Sentiment: POSITIVE

--Six sites across the U.S. are now engaged in Phase1b study Marlborough, Massachusetts--(Newsfile Corp. - November 19, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company exploring new pathways towards a cancer-free future, today announced it has completed the enrollment of its second patient cohort in its PH-762 Phase 1b dose-escalating clinical trial, and added a sixth clinical site in San Diego, CA. Phio recently presented new data from the ongoing clinical trial showing that, of the two patients who have completed treatment in the second dose cohort, one patient with cutaneous squamous cell carcinoma achieved a complete response (100% tumor clearance) while a second patient with squamous cell carcinoma achieved a partial response (90% tumor clearance).

Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
newsfilecorp.com14 November 2024 Sentiment: POSITIVE

Marlborough, Massachusetts--(Newsfile Corp. - November 14, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company exploring new pathways towards a cancer-free future by using its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells today reported its financial results for the quarter ended September 30, 2024 and provided a business update. Recent Corporate Updates The Phase 1b dose escalation clinical trial for our lead product candidate, PH-762, previously received a positive safety recommendation to advance to the next highest dose from the Safety Monitoring Committee (SMC) for the first cohort.

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
newsfilecorp.com01 November 2024 Sentiment: POSITIVE

Registration Link for Presentation and live Q&A to take place, Thursday, November 7 at 12:00 pm EST Marlborough Massachusetts--(Newsfile Corp. - November 1, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company creating new pathways towards a cancer-free future by using its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells announced today that management will present in the live Virtual Non-Deal Roadshow Series hosted by Renmark Financial Communications Inc. Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present on Thursday, November 7 at 12:00 pm EST.

Correction to Registration Link to Access Phio Pharmaceuticals' Presentation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
newsfilecorp.com18 October 2024 Sentiment: POSITIVE

Presentation and live Q&A to take place Wednesday, October 23, 2024, at 12 PM EDT Marlborough, Massachusetts--(Newsfile Corp. - October 18, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, announced today that management will present in the live Virtual Non-Deal Roadshow Series hosted by Renmark Financial Communications Inc. Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present on Wednesday, October 23, 2024, at 12 PM EDT.

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series
newsfilecorp.com18 October 2024 Sentiment: POSITIVE

Presentation and live Q&A to take place Wednesday, October 23, 2024, at 12 PM EDT Marlborough, Massachusetts--(Newsfile Corp. - October 18, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, announced today that management will present in the live Virtual Non-Deal Roadshow Series hosted by Renmark Financial Communications Inc. Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present on Wednesday, October 23, 2024, at 12 PM EDT.

Phio Announces Data Showcasing INTASYL's Role in Helping Immune Cells Target and Kill Cancer Cells
newsfilecorp.com07 October 2024 Sentiment: POSITIVE

INTASYL compounds also improve the functionality and outcomes of adoptive cell therapies such as NK, TIL and CAR-T Marlborough, Massachusetts--(Newsfile Corp. - October 7, 2024) - Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced that it is presenting data about its proprietary INTASYL platform and INTASYL compounds. INTASYL compounds offer precise targeting by silencing mRNA both intracellularly and extracellularly, significantly enhancing immune responses against cancer.

INTASYL Technology and Compounds to be Focus of Presentation at 20th Annual Meeting of Oligonucleotide Therapeutics Society
newsfilecorp.com25 September 2024 Sentiment: POSITIVE

--Data will be presented at the conference in October in Montreal Marlborough, Massachusetts--(Newsfile Corp. - September 25, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it is presenting data about INTASYL, its patented technology platform at the 20th Annual Oligonucleotide Therapeutics Society (OTS) Meeting. The conference will be held from October 6th-9th in Montreal, bringing together leading experts in oligonucleotide research.

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
newsfilecorp.com17 September 2024 Sentiment: POSITIVE

Presentation and live Q&A to take place Tuesday, September 24, 2024, at 12 PM EDT Marlborough, Massachusetts--(Newsfile Corp. - September 17, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, announced today that management will present in the live Virtual Non-Deal Roadshow Series hosted by Renmark Financial Communications Inc. Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present on Tuesday, September 24, 2024, at 12 PM EDT.

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
newsfilecorp.com29 August 2024 Sentiment: POSITIVE

Presentation and live Q&A to take place Thursday, September 5, 2024, at 12 PM EDT Marlborough, Massachusetts--(Newsfile Corp. - August 29, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, announced today that management will present in the live Virtual Non-Deal Roadshow Series hosted by Renmark Financial Communications Inc. Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present on Thursday, September 5, 2024, at 12 PM EDT.

Phio Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
newsfilecorp.com14 August 2024 Sentiment: POSITIVE

Marlborough, Massachusetts--(Newsfile Corp. - August 14, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today reported its financial results for the quarter ended June 30, 2024 and provided a business update. Recent Corporate Updates The Phase 1b clinical trial for our lead product candidate, PH-762, received a positive safety recommendation from the Safety Monitoring Committee (SMC).

  • 1(current)

What type of business is Phio Pharmaceuticals?

Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.

What sector is Phio Pharmaceuticals in?

Phio Pharmaceuticals is in the Healthcare sector

What industry is Phio Pharmaceuticals in?

Phio Pharmaceuticals is in the Biotechnology industry

What country is Phio Pharmaceuticals from?

Phio Pharmaceuticals is headquartered in United States

When did Phio Pharmaceuticals go public?

Phio Pharmaceuticals initial public offering (IPO) was on 10 May 2012

What is Phio Pharmaceuticals website?

https://phiopharma.com

Is Phio Pharmaceuticals in the S&P 500?

No, Phio Pharmaceuticals is not included in the S&P 500 index

Is Phio Pharmaceuticals in the NASDAQ 100?

No, Phio Pharmaceuticals is not included in the NASDAQ 100 index

Is Phio Pharmaceuticals in the Dow Jones?

No, Phio Pharmaceuticals is not included in the Dow Jones index

When was Phio Pharmaceuticals the previous earnings report?

No data

When does Phio Pharmaceuticals earnings report?

Next earnings report date is not announced yet